TY - JOUR A1 - Perkins, Daniel M. A1 - Perna, Andrea A1 - Adrian, Rita A1 - Cermeno, Pedro A1 - Gaedke, Ursula A1 - Huete-Ortega, Maria A1 - White, Ethan P. A1 - Yvon-Durocher, Gabriel T1 - Energetic equivalence underpins the size structure of tree and phytoplankton communities JF - Nature Communications N2 - The size structure of autotroph communities - the relative abundance of small vs. large individuals - shapes the functioning of ecosystems. Whether common mechanisms underpin the size structure of unicellular and multicellular autotrophs is, however, unknown. Using a global data compilation, we show that individual body masses in tree and phytoplankton communities follow power-law distributions and that the average exponents of these individual size distributions (ISD) differ. Phytoplankton communities are characterized by an average ISD exponent consistent with three-quarter-power scaling of metabolism with body mass and equivalence in energy use among mass classes. Tree communities deviate from this pattern in a manner consistent with equivalence in energy use among diameter size classes. Our findings suggest that whilst universal metabolic constraints ultimately underlie the emergent size structure of autotroph communities, divergent aspects of body size (volumetric vs. linear dimensions) shape the ecological outcome of metabolic scaling in forest vs. pelagic ecosystems. Y1 - 2019 U6 - https://doi.org/10.1038/s41467-018-08039-3 SN - 2041-1723 VL - 10 PB - Nature Publ. Group CY - London ER - TY - JOUR A1 - Steup, Martin T1 - Raum und Zahl in der Pflanzenphysiologie JF - Raum und Zahl Y1 - 2015 SN - 978-3-86464-082-7 SP - 77 EP - 109 PB - Trafo CY - Berlin ER - TY - JOUR A1 - Koc-Januchta, Marta A1 - Höffler, Tim A1 - Thoma, Gun-Brit A1 - Prechtl, Helmut A1 - Leutner, Detlev T1 - Visualizers versus verbalizers BT - Effects of cognitive style on learning with texts and pictures - An eye-tracking study JF - Computers in human behavior N2 - This study was conducted in order to examine the differences between visualizers and verbalizers in the way they gaze at pictures and texts while learning. Using a collection of questionnaires, college students were classified according to their visual or verbal cognitive style and were asked to learn about two different, in terms of subject and type of knowledge, topics by means of text-picture combinations. Eye-tracking was used to investigate their gaze behavior. The results show that visualizers spent significantly more time inspecting pictures than verbalizers, while verbalizers spent more time inspecting texts. Results also suggest that both visualizers' and verbalizers' way of learning is active but mostly within areas providing the source of information in line with their cognitive style (pictures or text). Verbalizers tended to enter non-informative, irrelevant areas of pictures sooner than visualizers. The comparison of learning outcomes showed that the group of visualizers achieved better results than the group of verbalizers on a comprehension test. KW - Cognitive style KW - Verbalizer KW - Visualizer KW - Eye-tracking KW - Multimedia learning Y1 - 2016 U6 - https://doi.org/10.1016/j.chb.2016.11.028 SN - 0747-5632 SN - 1873-7692 VL - 68 SP - 170 EP - 179 PB - Elsevier CY - Oxford ER - TY - JOUR A1 - Eckert, Silvia A1 - Herden, Jasmin A1 - Stift, Marc A1 - Durka, Walter A1 - Kleunen, Mark van A1 - Joshi, Jasmin Radha T1 - Traces of genetic but not epigenetic adaptation in the invasive goldenrod Solidago canadensis despite the absence of population structure JF - Zweitveröffentlichungen der Universität Potsdam : Mathematisch-Naturwissenschaftliche Reihe N2 - Biological invasions may result from multiple introductions, which might compensate for reduced gene pools caused by bottleneck events, but could also dilute adaptive processes. A previous common-garden experiment showed heritable latitudinal clines in fitness-related traits in the invasive goldenrod Solidago canadensis in Central Europe. These latitudinal clines remained stable even in plants chemically treated with zebularine to reduce epigenetic variation. However, despite the heritability of traits investigated, genetic isolation-by-distance was non-significant. Utilizing the same specimens, we applied a molecular analysis of (epi)genetic differentiation with standard and methylation-sensitive (MSAP) AFLPs. We tested whether this variation was spatially structured among populations and whether zebularine had altered epigenetic variation. Additionally, we used genome scans to mine for putative outlier loci susceptible to selection processes in the invaded range. Despite the absence of isolation-by-distance, we found spatial genetic neighborhoods among populations and two AFLP clusters differentiating northern and southern Solidago populations. Genetic and epigenetic diversity were significantly correlated, but not linked to phenotypic variation. Hence, no spatial epigenetic patterns were detected along the latitudinal gradient sampled. Applying genome-scan approaches (BAYESCAN, BAYESCENV, RDA, and LFMM), we found 51 genetic and epigenetic loci putatively responding to selection. One of these genetic loci was significantly more frequent in populations at the northern range. Also, one epigenetic locus was more frequent in populations in the southern range, but this pattern was lost under zebularine treatment. Our results point to some genetic, but not epigenetic adaptation processes along a large-scale latitudinal gradient of S. canadensis in its invasive range. T3 - Zweitveröffentlichungen der Universität Potsdam : Mathematisch-Naturwissenschaftliche Reihe - 1271 KW - AFLP KW - MSAP KW - cytosine methylation KW - spatial autocorrelation KW - genome scan Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus4-566758 SN - 1866-8372 SP - 1 EP - 17 PB - Universitätsverlag Potsdam CY - Potsdam ER - TY - THES A1 - Gopalakrishnan, Sathej T1 - Mathematical modelling of host-disease-drug interactions in HIV disease T1 - Mathematische Modellierung von Pathogen-Wirkstoff-Wirt-Interaktionen im Kontext der HIV Erkrankung N2 - The human immunodeficiency virus (HIV) has resisted nearly three decades of efforts targeting a cure. Sustained suppression of the virus has remained a challenge, mainly due to the remarkable evolutionary adaptation that the virus exhibits by the accumulation of drug-resistant mutations in its genome. Current therapeutic strategies aim at achieving and maintaining a low viral burden and typically involve multiple drugs. The choice of optimal combinations of these drugs is crucial, particularly in the background of treatment failure having occurred previously with certain other drugs. An understanding of the dynamics of viral mutant genotypes aids in the assessment of treatment failure with a certain drug combination, and exploring potential salvage treatment regimens. Mathematical models of viral dynamics have proved invaluable in understanding the viral life cycle and the impact of antiretroviral drugs. However, such models typically use simplified and coarse-grained mutation schemes, that curbs the extent of their application to drug-specific clinical mutation data, in order to assess potential next-line therapies. Statistical models of mutation accumulation have served well in dissecting mechanisms of resistance evolution by reconstructing mutation pathways under different drug-environments. While these models perform well in predicting treatment outcomes by statistical learning, they do not incorporate drug effect mechanistically. Additionally, due to an inherent lack of temporal features in such models, they are less informative on aspects such as predicting mutational abundance at treatment failure. This limits their application in analyzing the pharmacology of antiretroviral drugs, in particular, time-dependent characteristics of HIV therapy such as pharmacokinetics and pharmacodynamics, and also in understanding the impact of drug efficacy on mutation dynamics. In this thesis, we develop an integrated model of in vivo viral dynamics incorporating drug-specific mutation schemes learned from clinical data. Our combined modelling approach enables us to study the dynamics of different mutant genotypes and assess mutational abundance at virological failure. As an application of our model, we estimate in vivo fitness characteristics of viral mutants under different drug environments. Our approach also extends naturally to multiple-drug therapies. Further, we demonstrate the versatility of our model by showing how it can be modified to incorporate recently elucidated mechanisms of drug action including molecules that target host factors. Additionally, we address another important aspect in the clinical management of HIV disease, namely drug pharmacokinetics. It is clear that time-dependent changes in in vivo drug concentration could have an impact on the antiviral effect, and also influence decisions on dosing intervals. We present a framework that provides an integrated understanding of key characteristics of multiple-dosing regimens including drug accumulation ratios and half-lifes, and then explore the impact of drug pharmacokinetics on viral suppression. Finally, parameter identifiability in such nonlinear models of viral dynamics is always a concern, and we investigate techniques that alleviate this issue in our setting. N2 - Das Humane Immundefiecienz-Virus (HIV) widerstanden hat fast drei Jahrzehnten eff Orts targeting eine Heilung. Eine anhaltende Unterdrückung des Virus hat noch eine Herausforderung, vor allem aufgrund der bemerkenswerten evolutionären Anpassung, dass das Virus Exponate durch die Ansammlung von Medikamenten-resistenten Mutationen in seinem Genom. Aktuelle therapeutische Strategien zielen auf das Erreichen und die Erhaltung einer niedrigen virale Belastung und umfassen in der Regel mehrere Medikamente. Die Wahl der optimalen Kombinationen dieser Medikamente ist von entscheidender Bedeutung, besonders im Hintergrund der Behandlung Fehler eingetreten, die zuvor mit bestimmten anderen Medikamenten. Ein Verständnis für die Dynamik der viralen mutierten Genotypen Aids in die Bewertung der Behandlung Fehler mit einer bestimmten Kombination und der Erkundung potenzieller Bergung Behandlungsschemata. Mathematische Modelle für virale Dynamik haben sich als unschätzbar erwiesen hat im Verständnis der viralen Lebenszyklus und die Auswirkungen von antiretroviralen Medikamenten. Allerdings sind solche Modelle verwenden in der Regel simplified und grobkörnigen Mutation Regelungen, dass Aufkantungen den Umfang ihrer Anwendung auf Arzneimittel-ganz speziellec Mutation klinische Daten, um zu beurteilen, mögliche nächste-line Therapien. Statistische Modelle der Mutation Anhäufung gedient haben gut in präparieren Mechanismen der Resistenz Evolution durch Mutation Rekonstruktion Pathways unter verschiedenen Medikamenten-Umgebungen. Während diese Modelle führen gut in der Vorhersage der Ergebnisse der Behandlung durch statistische lernen, sie enthalten keine Droge E ffect mechanistisch. Darüber hinaus aufgrund einer innewohnenden Mangel an zeitlichen Funktionen in solchen Modellen, sie sind weniger informativ auf Aspekte wie die Vorhersage mutational Fülle an Versagen der Behandlung. Dies schränkt die Anwendung in der Analyse der Pharmakologie von antiretroviralen Medikamenten, insbesondere, Zeit-abhängige Merkmale der HIV-Therapie wie Pharmakokinetik und Pharmakodynamik, und auch in dem Verständnis der Auswirkungen von Drogen e fficacy auf Mutation Dynamik. In dieser Arbeit, die wir bei der Entwicklung eines integrierten Modells von In-vivo-virale Dynamik Einbeziehung drug-ganz speziellec Mutation Systeme gelernt aus den klinischen Daten. Unsere kombinierten Modellansatz ermöglicht uns die Untersuchung der Dynamik von diff schiedene mutierten Genotypen und bewerten mutational Fülle an virologischem Versagen. Als Anwendung unseres Modells schätzen wir In-vivo-fitness Merkmale der viralen Mutanten unter di fferent drug Umgebungen. Unser Ansatz erstreckt sich auch natürlich auf mehrere-Therapien. Weitere zeigen wir die Vielseitigkeit unseres Modells zeigen, wie es können Modified zu integrieren kürzlich aufgeklärt Mechanismen der Drug Action einschließlich Molekülen, dass target host Faktoren. Zusätzlich haben wir Adresse ein weiterer wichtiger Aspekt in der klinischen Management der HIV-Erkrankung, das heißt Drogen Pharmakokinetik. Es ist klar, dass die Zeit-abhängige Änderungen in In-vivo-Wirkstoffkonzentration könnten die Auswirkungen auf die antivirale E ffect und haben auch Einfluss auf die Entscheidungen über Dosierungsintervalle. Wir präsentieren ein Framework, bietet ein integriertes Verständnis der wichtigsten Merkmale von mehreren Dosierungsschemata einschließlich Kumulation Übersetzungen und Halbwertszeiten, und untersuchen Sie die Auswirkungen von Drogen auf die Pharmakokinetik Virussuppression. Schließlich, Parameter identifiFähigkeit in solchen nichtlineare Modelle der virale Dynamik ist immer ein Anliegen, und wir untersuchen Methoden, um dieses Problem in unserer Einstellung. KW - HIV KW - mathematical modelling KW - viral fitness KW - pharmacokinetics KW - parameter estimation KW - HIV Erkrankung KW - Pharmakokinetik KW - Fitness KW - mathematische Modellierung KW - Kombinationstherapie Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus4-100100 ER - TY - GEN A1 - Weisser, Karin A1 - Stübler, Sabine A1 - Matheis, Walter A1 - Huisinga, Wilhelm T1 - Towards toxicokinetic modelling of aluminium exposure from adjuvants in medicinal products T2 - Regulatory toxicology and pharmacology : official journal of the International Society for Regulatory Toxicology and Pharmacology N2 - As a potentially toxic agent on nervous system and bone, the safety of aluminium exposure from adjuvants in vaccines and subcutaneous immune therapy (SCIT) products has to be continuously reevaluated, especially regarding concomitant administrations. For this purpose, knowledge on absorption and disposition of aluminium in plasma and tissues is essential. Pharmacokinetic data after vaccination in humans, however, are not available, and for methodological and ethical reasons difficult to obtain. To overcome these limitations, we discuss the possibility of an in vitro-in silico approach combining a toxicokinetic model for aluminium disposition with biorelevant kinetic absorption parameters from adjuvants. We critically review available kinetic aluminium-26 data for model building and, on the basis of a reparameterized toxicokinetic model (Nolte et al., 2001), we identify main modelling gaps. The potential of in vitro dissolution experiments for the prediction of intramuscular absorption kinetics of aluminium after vaccination is explored. It becomes apparent that there is need for detailed in vitro dissolution and in vivo absorption data to establish an in vitro-in vivo correlation (IVIVC) for aluminium adjuvants. We conclude that a combination of new experimental data and further refinement of the Nolte model has the potential to fill a gap in aluminium risk assessment. (C) 2017 Elsevier Inc. All rights reserved. KW - Aluminium KW - Aluminium adjuvants KW - Absorption kinetics KW - Toxicokinetic modelling KW - In vitro dissolution Y1 - 2017 U6 - https://doi.org/10.1016/j.yrtph.2017.02.018 SN - 0273-2300 SN - 1096-0295 VL - 88 SP - 310 EP - 321 PB - Elsevier CY - San Diego ER -